Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax,
and obinutuzumab -- as a possible treatment for chronic lymphocytic leukemia (CLL).
The drugs involved in this study are:
- Acalabrutinib
- Venetoclax
- Obinutuzmab